

ADVANCED BASAL CELL CARCINOMA: HOW TO NAVIGATE CHALLENGING CLINICAL SCENARIOS WITH SYSTEMIC TREATMENT

REFERENCES

1. Ally MS, et al. Effect of calcium channel blockade on vismodegib-induced muscle cramps. *JAMA Dermatol*. 2015;151(10):1132-1134.
2. American Cancer Society. <https://www.cancer.org/cancer/basal-and-squamous-cell-skin-cancer/about/key-statistics.html>. Accessed November 23, 2020.
3. Atwood SX, et al. Smoothed variants explain the majority of drug resistance in basal cell carcinoma. *Cancer Cell*. 2015;27(3):342-353.
4. Basset-Seguín N, et al. Vismodegib in patients with advanced basal cell carcinoma: Primary analysis of STEVIE, an international, open-label trial. *Eur J Cancer*. 2017;86:334-348.
5. Basset-Seguín N, et al. Vismodegib in patients with advanced basal cell carcinoma (STEVIE): a pre-planned interim analysis of an international, open-label trial. *Lancet Oncol*. 2015;16(6):729-736.
6. Bichakjian C, et al. Guidelines of care for the management of basal cell carcinoma. *J Am Acad Dermatol*. 2018;78:540-559.
7. Danial C, et al. An investigator-initiated open-label trial of sonidegib in advanced basal cell carcinoma patients resistant to vismodegib. *Clin Cancer Res*. 2016;22(6):1325-1329.
8. Dessinioti C, et al. A practical guide for the follow up of patients with advanced basal cell carcinoma during treatment with hedgehog pathway inhibitors. *Oncologist*. 2019;24:e755-e764.
9. Dinehart M, et al. L-carnitine reduces muscle cramps in patients taking vismodegib. *Skin*. 2018;2(2):90-95.
10. Dreno B, et al. Two intermittent vismodegib dosing regimens in patients with multiple basal-cell carcinomas (MIKIE): a randomised, regimen-controlled, double-blind, phase 2 trial. *Lancet Oncol*. 2017;18(3):404-412.
11. Dummer R, et al. Long-term efficacy and safety of sonidegib in patients with advanced basal cell carcinoma: 42-month analysis of the phase II randomized, double-blind BOLT study. *Br J Dermatol*. 2020;182:1369-1378.
12. Erivedge [package insert]. South San Francisco, CA: Genentech USA, Inc.; August 2020.
13. Euvrard S et al. Skin cancers after organ transplantation. *N Engl J Med*. 2003;348(17):1681-1691.
14. Falchook GS, et al. Responses of metastatic basal cell and cutaneous squamous cell carcinomas to anti-PD1 monoclonal antibody REGN2810. *J Immunother Cancer*. 2016;4:70.
15. Fania L, et al. Basal cell carcinoma: From pathophysiology to novel therapeutic approaches. *Biomedicines*. 2020;8:449.
16. Fisher MS, et al. Suppressor T lymphocytes control the development of primary skin cancers in ultraviolet-irradiated mice. *Science*. 1982;216(4550):1133-1134.
17. Gollnick HA, et al. Recurrence rate of superficial basal cell carcinoma following treatment with imiquimod 5% cream: conclusion of a 5-year long-term follow-up study in Europe. *Eur J Dermatol*. 2008;18(6):677-682.
18. Ikeda S, et al. Metastatic basal cell carcinoma with amplification of PD-L1: exceptional response to anti-PD1 therapy. *NPJ Genom Med*. 2016;1:16037.
19. Lacouture ME, et al. Characterization and management of hedgehog pathway inhibitor-related adverse events in patients with advanced basal cell carcinoma. *Oncologist*. 2016;21(10):1218-1229.
20. Lear JT, et al. Long-term efficacy and safety of sonidegib in patients with locally advanced and metastatic basal cell carcinoma: 30-month analysis of the randomized phase 2 BOLT study. *J Eur Acad Dermatol Venereol*. 2018;32:372-381.
21. Migden M, et al. Burden and treatment patterns of advanced basal cell carcinoma among commercially insured patients in a United States database from 2010 to 2014. *J Am Acad Dermatol*. 2017;77(1):55-62.
22. Migden M, et al. Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial. *Lancet Oncol*. 2015;16(6):716-728.
23. National Comprehensive Cancer Network. https://www.nccn.org/professionals/physician_gls/pdf/nmsc.pdf. Accessed November 24, 2020.

ADVANCED BASAL CELL CARCINOMA: HOW TO NAVIGATE CHALLENGING CLINICAL SCENARIOS WITH SYSTEMIC TREATMENT



24. Odomzo [package insert]. Cranbury, NJ: Sun Pharmaceutical Industries, Inc.; July 2020.
25. Sekulic A, et al. Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study. *BMC Cancer*. 2017;17:332.
26. Sekulic A, et al. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. *N Engl J Med*. 2012;366(23):2171-2179.
27. Sharpe HJ, et al. Genomic analysis of smoothened inhibitor resistance in basal cell carcinoma. *Cancer Cell*. 2015;27(3):327-341.
28. Skin Cancer Foundation. <https://www.skincancer.org/skin-cancer-information/basal-cell-carcinoma/>. Accessed November 24, 2020.
29. Stratigos AJ, et al. Primary analysis of phase II results for cemiplimab in patients (pts) with locally advanced basal cell carcinoma (laBCC) who progress on or are intolerant to hedgehog inhibitors (HHIs). *Ann Oncol*. 2020;31(suppl 4):S1175-S1176. Abstract LBA47.
30. Tampa M, et al. Recent advances in signaling pathways comprehension as carcinogenesis triggers in basal cell carcinoma. *J Clin Med*. 2020;9:3010.
31. Wu X, et al. Burden of basal cell carcinoma in USA. *Future Oncol*. 2015;11(22):2967-2974.